AbstractHIVViral Hepatitis and Liver DiseasePuerto Rico Meeting on Hepatitis & HIV 2019Heterogeneity in priorities for continuing education training among clinicians providing (or not!) HIV and HCV clinical servicesView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePuerto Rico Meeting on Hepatitis & HIV 2019Automated electrochemiluminescence assay could be used for screening hepatitis B and C markers in dried blood spot samples?View Abstract
AbstractHIVViral Hepatitis and Liver DiseasePuerto Rico Meeting on Hepatitis & HIV 201996 Week efficacy and safety of B/F/TAF in treatment-naïve adults and adults ≥ 50 yearsView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePuerto Rico Meeting on Hepatitis & HIV 2019Tenofovir alafenamide vs tenofovir DF in women: Pooled analysis of 7 clinical trialsView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePuerto Rico Meeting on Hepatitis & HIV 2019Associations between hepatitis C and social determinants of health in a sample of injecting drug users living with HIV in Puerto RicoView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePuerto Rico Meeting on Hepatitis & HIV 2019Sociodemographic, health-related factors and behavioral practices among people who inject drugs: Data from the PR NHBS-PWID 3 (2012) and NHBS-PWID 4 (2015)View Abstract
AbstractHIVViral Hepatitis and Liver DiseasePuerto Rico Meeting on Hepatitis & HIV 2019Provider-Initiated HIV testing predictors among heterosexuals at increased risk of HIV in Puerto Rico: Data from NHBS – HET cycle, 2016View Abstract
AbstractHIVViral Hepatitis and Liver DiseasePuerto Rico Meeting on Hepatitis & HIV 2019Hurricane Maria’s viral impact: HIV care outcomes among substance users in Puerto Rico following hurricane MariaView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePuerto Rico Meeting on Hepatitis & HIV 2019Clinical case presentation: A preliminary profile of common co-morbidities and risk practices in a sample of HIV/HCV co-infected patients in Puerto RicoView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePuerto Rico Meeting on Hepatitis & HIV 2019A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically suppressed HIV-1 infected adult subjects harboring the NRTI resistance mutation M184V and/or M184I (GS-USView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePuerto Rico Meeting on Hepatitis & HIV 2019Acceptability and concerns over the use of PrEP in Puerto RicoView Abstract
AbstractHIVINTEREST 2020Presence of HIV drug resistance in people re-initiating first-line antiretroviral therapy after treatment interruption in NamibiaView Abstract
